![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir
|
|
|
20th International Workshop on Clinical Pharmacology of HIV
Hepatitis & Other Antiviral Drugs
May 14-16, 2019. Noordwijk, the Netherlands
Reported by Jules Levin
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands
Kunal Taskar1, Parul Patel2, Simon Cozens1, Helen Tracey1, Jackie Bloomer1, Kelong Han3, Susan Ford3, Mark Baker4 and Aarti Patel1
1GlaxoSmithKline, Ware, UK; 2ViiV Healthcare, RTP, USA; 3GlaxoSmithKline, PA, USA; 4 ViiV Healthcare, Nyon, Switzerland.
![0526191](../images/052619/052619-2/0526191.gif)
![0526192](../images/052619/052619-2/0526192.gif)
![0526193](../images/052619/052619-2/0526193.gif)
![0526194](../images/052619/052619-2/0526194.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|